172 related articles for article (PubMed ID: 26712869)
21. Implementing specificity of HPV-DNA primary screening in a successful organised cervical cancer prevention programme.
Zappacosta R; Caraceni D; Ciccocioppo L; Rotondo T; Capanna S; Gatta DM; D'Angelo C; Rosini S
Gynecol Oncol; 2013 Mar; 128(3):427-32. PubMed ID: 23200910
[TBL] [Abstract][Full Text] [Related]
22. Comparison of CINtec PLUS cytology and cobas HPV test for triaging Canadian patients with LSIL cytology referred to colposcopy: A two-year prospective study.
Gilbert L; Ratnam S; Jang D; Alaghehbandan R; Schell M; Needle R; Ecobichon-Morris A; Wadhawan A; Costescu D; Elit L; Wang P; Zahariadis G; Chernesky M
Cancer Biomark; 2022; 34(3):347-358. PubMed ID: 35001877
[TBL] [Abstract][Full Text] [Related]
23. Clinical validation of p16/Ki-67 dual-stained cytology triage of HPV-positive women: Results from the IMPACT trial.
Wright TC; Stoler MH; Ranger-Moore J; Fang Q; Volkir P; Safaeian M; Ridder R
Int J Cancer; 2022 Feb; 150(3):461-471. PubMed ID: 34536311
[TBL] [Abstract][Full Text] [Related]
24. Immunocytochemical colocalization of P16(INK4a) and Ki-67 predicts CIN2/3 and AIS/adenocarcinoma.
Singh M; Mockler D; Akalin A; Burke S; Shroyer A; Shroyer KR
Cancer Cytopathol; 2012 Feb; 120(1):26-34. PubMed ID: 22162342
[TBL] [Abstract][Full Text] [Related]
25. Cervical cancer screening cotesting with cytology and MRNA HPV E6/E7 yields high rates of CIN2+ lesions in young women.
Granados R; Tellez-Safina H; Solis I; Mateos F; Rodriguez-Barbero JM; Aramburu JA; Huertas MA; Bajo P; Camarmo E; Corrales T; Medina P; Calvo B; Martin E; Anta L; Zamora M; Alcaide T
Diagn Cytopathol; 2017 Dec; 45(12):1065-1072. PubMed ID: 28949442
[TBL] [Abstract][Full Text] [Related]
26. Clinical evaluation of p16
Rezhake R; Wang Y; Chen F; Hu SY; Zhang X; Cao J; Qiao YL; Zhao FH; Arbyn M
Cancer Cytopathol; 2021 Sep; 129(9):679-692. PubMed ID: 33826790
[TBL] [Abstract][Full Text] [Related]
27. Importance of addition of HPV DNA testing to the cytology based cervical cancer screening and triage of findings with p16/Ki67 immunocytochemistry staining in 35 and 45 years old women LIBUSE trial data analysis.
Sláma J; Dvořák V; Trnková M; Skřivánek A; Hurdálková K; Ovesná P; Nováčková M
Ceska Gynekol; 2020; 85(6):368-374. PubMed ID: 33711896
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic performance of the E6/E7 mRNA-based Optimygene HR-HPV RT-qDx assay for cervical cancer screening.
Wang HY; Kim H; Park KH
Int J Infect Dis; 2019 Jan; 78():22-30. PubMed ID: 30248464
[TBL] [Abstract][Full Text] [Related]
29. Performance of HPV E6/E7 mRNA assay as primary screening test: Results from the NTCC2 trial.
Giorgi Rossi P; Ronco G; Mancuso P; Carozzi F; Allia E; Bisanzi S; Gillio-Tos A; De Marco L; Rizzolo R; Gustinucci D; Del Mistro A; Frayle H; Confortini M; Iossa A; Cesarini E; Bulletti S; Passamonti B; Gori S; Toniolo L; Barca A; Bonvicini L; Venturelli F; Benevolo M;
Int J Cancer; 2022 Oct; 151(7):1047-1058. PubMed ID: 35579975
[TBL] [Abstract][Full Text] [Related]
30. Clinical Utility of CINtec PLUS Triage in Equivocal Cervical Cytology and Human Papillomavirus Primary Screening.
McMenamin M; McKenna M; McDowell A
Am J Clin Pathol; 2018 Oct; 150(6):512-521. PubMed ID: 30169728
[TBL] [Abstract][Full Text] [Related]
31. Human papillomavirus mRNA testing for the detection of anal high-grade squamous intraepithelial lesions in men who have sex with men infected with HIV.
Sendagorta E; Romero MP; Bernardino JI; Beato MJ; Alvarez-Gallego M; Herranz P
J Med Virol; 2015 Aug; 87(8):1397-403. PubMed ID: 25940055
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the detection of HPV-16, 18, 31, 33, and 45 by type-specific DNA- and E6/E7 mRNA-based assays of HPV DNA positive women with abnormal Pap smears.
Salimović-Bešić I; Tomić-Čiča A; Smailji A; Hukić M
J Virol Methods; 2013 Dec; 194(1-2):222-8. PubMed ID: 24036071
[TBL] [Abstract][Full Text] [Related]
33. Clinical utility of p16/Ki67 dual-stain cytology for detection of cervical intraepithelial neoplasia grade two or worse in women with a transformation zone type 3: A cross-sectional study.
Gustafson LW; Tranberg M; Christensen PN; Brøndum R; Wentzensen N; Clarke MA; Andersen B; Petersen LK; Bor P; Hammer A
BJOG; 2023 Jan; 130(2):202-209. PubMed ID: 35686564
[TBL] [Abstract][Full Text] [Related]
34. Combination of p16(INK4a) /Ki67 immunocytology and HPV polymerase chain reaction for the noninvasive analysis of HPV involvement in head and neck cancer.
Linxweiler M; Bochen F; Wemmert S; Lerner C; Hasenfus A; Bohle RM; Al-Kadah B; Takacs ZF; Smola S; Schick B
Cancer Cytopathol; 2015 Apr; 123(4):219-29. PubMed ID: 25557267
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic performance of HPV E6/E7 mRNA testing towards HPV-DNA testing and p16/Ki67 immunostaining as a biomarker of high-risk HPV recurrence in Greek women surgically treated for their cervical lesions.
Carcea F; Vavoulidis E; Petousis S; Papandreou P; Siarkou CM; Nasioutziki M; Papanikolaou A; Dinas K; Daniilidis A
J Obstet Gynaecol Res; 2021 Oct; 47(10):3607-3617. PubMed ID: 34374179
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the performance of the NucliSENS EasyQ HPV E6/E7 mRNA assay and HPV DNA chip for testing squamous cell lesions of the uterine cervix.
Munkhdelger J; Choi Y; Lee D; Kim S; Kim G; Park S; Choi E; Jin H; Jeon BY; Lee H; Park KH
Diagn Microbiol Infect Dis; 2014 Aug; 79(4):422-7. PubMed ID: 24856365
[TBL] [Abstract][Full Text] [Related]
37. p16/Ki-67 co-expression associates high risk human papillomavirus persistence and cervical histopathology: a 3-year cohort study in China.
Yu LL; Guo HQ; Lei XQ; Qin Y; Wu ZN; Kang LN; Zhang X; Qiao YL; Chen W
Oncotarget; 2016 Oct; 7(40):64810-64819. PubMed ID: 27588487
[TBL] [Abstract][Full Text] [Related]
38. Triaging abnormal cervical cancer screening tests using p16INK4a detection by ELISA on fresh cervical samples.
Leung SOA; Feldman S; Kalyanaraman R; Shanmugam V; Worley MJ; Berkowitz RS; Horowitz NS; Feltmate CM; Muto MG; Lee LJ; King MT; Einarsson JI; Ajao MO; Elias KM
Am J Reprod Immunol; 2021 Jul; 86(1):e13394. PubMed ID: 33501727
[TBL] [Abstract][Full Text] [Related]
39. Performance of P16/Ki67 dual staining in triaging hr-HPV-positive population during cervical Cancer screening in the younger women.
Qian QP; Zhang X; Ding B; Jiang SW; Li ZM; Ren ML; Shen Y
Clin Chim Acta; 2018 Aug; 483():281-285. PubMed ID: 29758205
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic performance of dual-staining cytology for cervical cancer screening: A systematic literature review.
Tjalma WAA
Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():275-280. PubMed ID: 28086168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
